Protocol Ledger

NCT07379047 · Phase II/III · RECRUITING

Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

Interventional Phase II/III clinical trial protocol NCT07379047 sponsored by Ningbo Newbay Technology Development Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-05-11 Enrollment: 255 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07379047
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)255 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07379047
Protocol FieldVerified Registry Value
NCT IdentifierNCT07379047
Consolidated Lead SponsorNingbo Newbay Technology Development Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment255 participants (ESTIMATED)
Registered Start Date2026-05-11
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI